Suppr超能文献

氟罗沙星在皮肤及皮肤结构感染患者中的稳态药代动力学。

Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.

作者信息

Heim-Duthoy K, Peltier G, Awni W

机构信息

Department of Medicine, Hennepin County Medical Center, College of Pharmacy, University of Minnesota, Minneapolis 55415.

出版信息

Antimicrob Agents Chemother. 1990 May;34(5):922-3. doi: 10.1128/AAC.34.5.922.

Abstract

Steady-state pharmacokinetics of oral fleroxacin were studied in six males who had skin or skin structure infections and who were receiving 400 mg of fleroxacin once a day. Blood samples (n = 10) and total urine output were collected during a 24-h dosing interval. Fleroxacin concentrations in serum and urine were determined by high-performance liquid chromatography. The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively. The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively. Fleroxacin disposition in this patient population was similar to that in noninfected volunteers with normal renal function.

摘要

对6名患有皮肤或皮肤结构感染且每天接受400毫克氟罗沙星治疗的男性进行了口服氟罗沙星的稳态药代动力学研究。在24小时给药间隔期间采集血样(n = 10)和总尿量。通过高效液相色谱法测定血清和尿液中的氟罗沙星浓度。血清中的最大浓度及达到该最大值的时间分别为6.2±2.2微克/毫升和0.94±0.62小时。吸收半衰期、α半衰期、β半衰期、表观稳态分布容积、表观总体清除率和肾清除率分别为0.56±0.37小时、0.78±0.51小时、10.56±1.40小时、0.85±0.31升/千克、129.2±19.6毫升/分钟和53.3±16.7毫升/分钟。该患者群体中氟罗沙星的处置情况与肾功能正常的未感染志愿者相似。

相似文献

1
Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Antimicrob Agents Chemother. 1990 May;34(5):922-3. doi: 10.1128/AAC.34.5.922.
2
Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:155-67. doi: 10.1093/jac/22.supplement_d.155.
3
Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:133-44. doi: 10.1093/jac/22.supplement_d.133.
4
Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
Antimicrob Agents Chemother. 1988 Oct;32(10):1515-20. doi: 10.1128/AAC.32.10.1515.
5
Single and multiple dose pharmacokinetics of fleroxacin.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:145-54. doi: 10.1093/jac/22.supplement_d.145.
6
Metabolism of fleroxacin in man.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:169-78. doi: 10.1093/jac/22.supplement_d.169.
7
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Clin Pharmacokinet. 1990 Jul;19(1):80-8. doi: 10.2165/00003088-199019010-00006.
8
Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Antimicrob Agents Chemother. 1990 Dec;34(12):2375-80. doi: 10.1128/AAC.34.12.2375.
9
Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Antimicrob Agents Chemother. 1987 Dec;31(12):1909-14. doi: 10.1128/AAC.31.12.1909.
10
Pharmacokinetics of cefonicid in patients with skin and skin structure infections.
Antimicrob Agents Chemother. 1988 Apr;32(4):485-7. doi: 10.1128/AAC.32.4.485.

引用本文的文献

1
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
2
Pharmacokinetics of quinolones: newer aspects.
Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):267-74. doi: 10.1007/BF01967000.
3
Fleroxacin clinical pharmacokinetics.
Clin Pharmacokinet. 1992 Feb;22(2):116-31. doi: 10.2165/00003088-199222020-00003.

本文引用的文献

1
Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.
Antimicrob Agents Chemother. 1983 Jan;23(1):125-32. doi: 10.1128/AAC.23.1.125.
2
Pharmacokinetics of aztreonam in patients with gram-negative infections.
Antimicrob Agents Chemother. 1985 Jan;27(1):16-20. doi: 10.1128/AAC.27.1.16.
3
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
Antimicrob Agents Chemother. 1987 Sep;31(9):1420-2. doi: 10.1128/AAC.31.9.1420.
4
Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis.
Int J Clin Pharmacol Ther Toxicol. 1987 Jul;25(7):354-62.
6
Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Antimicrob Agents Chemother. 1987 Dec;31(12):1909-14. doi: 10.1128/AAC.31.12.1909.
8
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
J Antimicrob Chemother. 1987 Sep;20(3):363-72. doi: 10.1093/jac/20.3.363.
9
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
Antimicrob Agents Chemother. 1987 Feb;31(2):161-3. doi: 10.1128/AAC.31.2.161.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验